SWOG clinical trial number
SWOG-9011
High Dose Etoposide, Cyclophosphamide and Either Fractionated Total Body Irradiation or Carmustine Combined with Autologous Bone Marrow Rescue for Refractory or Relapsed Hodgkin's Disease
Closed
Phase
Accrual
90%
Published
Abbreviated Title
High Dose Etoposide, Cyclophosphamide and Either Fractionated Total Body Irradiation or Carmustine Combined with Autologous Bone Marrow Rescue for Refractory or Relapsed Hodgkin's Disease
Activated
04/15/1990
Closed
12/01/1995
Research committees
Lymphoma
Publication Information Expand/Collapse
2003
The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial
1996
Single fraction high dose chemotherapy with or without total body irradiation (TBI) and an autologous bone marrow transplant (ABMT) for patients with relapsed/refractory Hodgkin's disease: High survival rate in chemoresistant disease. A Southwest Oncology Group (SWOG) trial.
Other Clinical Trials
SWOG Clinical Trial Number
S2308
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
08/01/2024
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
S2207
Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
06/30/2023
Accrual
12%
Open
Phase
SWOG Clinical Trial Number
CTSU/AHOD2131
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Research Committee(s)
Lymphoma
Immunomolecular Therapeutics
Activated
04/28/2023
Open
Phase